WO2005033694A3 - Novel antisense oligomers and use thereof - Google Patents

Novel antisense oligomers and use thereof Download PDF

Info

Publication number
WO2005033694A3
WO2005033694A3 PCT/BE2004/000142 BE2004000142W WO2005033694A3 WO 2005033694 A3 WO2005033694 A3 WO 2005033694A3 BE 2004000142 W BE2004000142 W BE 2004000142W WO 2005033694 A3 WO2005033694 A3 WO 2005033694A3
Authority
WO
WIPO (PCT)
Prior art keywords
oligomers
bridging
antisense
exon
genomic dna
Prior art date
Application number
PCT/BE2004/000142
Other languages
French (fr)
Other versions
WO2005033694A8 (en
WO2005033694A2 (en
Inventor
August Verbruggen
Dirk Elewaut
Jun Wang
Original Assignee
Univ Gent
August Verbruggen
Dirk Elewaut
Jun Wang
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Gent, August Verbruggen, Dirk Elewaut, Jun Wang filed Critical Univ Gent
Priority to EP04761503A priority Critical patent/EP1671116A2/en
Publication of WO2005033694A2 publication Critical patent/WO2005033694A2/en
Publication of WO2005033694A3 publication Critical patent/WO2005033694A3/en
Publication of WO2005033694A8 publication Critical patent/WO2005033694A8/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/322—2'-R Modification

Abstract

The invention relates to the use of a novel type of antisense oligomers for use in the in vitro or in vivo inhibition of gene expression of a target gene. These oligomers, called exon-bridging oligomers are complementary to those parts of a spliced mRNA which are derived from two adjacent exons in the primary RNA transcript, and are called exon-bridging antisense oligomers. These oligomers have no complimentarity to genomic DNA. These oligomers can be used to performs antisense inhibition with less aspecific binding to genomic DNA. The exon-bridging oligomers are suitable for inhibiting Interleukin1 type I Receptor in, for instance, chondrocytes, and are suitable for the prevention or treatment of osteoarthritis.
PCT/BE2004/000142 2003-10-06 2004-10-06 Novel antisense oligomers and use thereof WO2005033694A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP04761503A EP1671116A2 (en) 2003-10-06 2004-10-06 Novel antisense oligomers and use thereof

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US50895903P 2003-10-06 2003-10-06
US60/508,959 2003-10-06

Publications (3)

Publication Number Publication Date
WO2005033694A2 WO2005033694A2 (en) 2005-04-14
WO2005033694A3 true WO2005033694A3 (en) 2005-10-20
WO2005033694A8 WO2005033694A8 (en) 2006-05-04

Family

ID=34421795

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/BE2004/000142 WO2005033694A2 (en) 2003-10-06 2004-10-06 Novel antisense oligomers and use thereof

Country Status (2)

Country Link
EP (1) EP1671116A2 (en)
WO (1) WO2005033694A2 (en)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5856099A (en) * 1996-05-21 1999-01-05 Isis Pharmaceuticals, Inc. Antisense compositions and methods for modulating type I interleukin-1 receptor expression

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5856099A (en) * 1996-05-21 1999-01-05 Isis Pharmaceuticals, Inc. Antisense compositions and methods for modulating type I interleukin-1 receptor expression

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
BURCH R M ET AL: "OLIGONUCLEOTIDES ANTISENSE TO THE INTERLEUKIN 1 RECEPTOR MRNA BLOCKTHE EFFECTS OF INTERLEUKIN 1 IN CULTURED MURINE AND HUMAN FIBROBLASTS AND IN MICE", JOURNAL OF CLINICAL INVESTIGATION, NEW YORK, NY, US, vol. 88, October 1991 (1991-10-01), pages 1190 - 1196, XP000925602, ISSN: 0021-9738 *
DEMOOR J M ET AL: "ANTISENSE NUCLEIC ACIDS TARGETED TO THE THYMIDYLATE SYNTHASE (TS) MRNA TRANSLATION START SITE STIMULATE TS GENE TRANSCRIPTION", EXPERIMENTAL CELL RESEARCH, SAN DIEGO, CA, US, vol. 243, 1998, pages 11 - 21, XP002923758, ISSN: 0014-4827 *
MIRAGLIA L ET AL: "INHIBITION OF INTERLEUKIN-1 TYPE I RECEPTOR EXPRESSION IN HUMAN CELL-LINES BY AN ANTISENSE PHOSPHOROTHIOATE OLIGODEOXYNUCLEOTIDE", INTERNATIONAL JOURNAL OF IMMUNOPHARMACOLOGY, ELMSFORD,NY, US, vol. 18, no. 4, 1996, pages 227 - 240, XP001002842, ISSN: 0192-0561 *
See also references of EP1671116A2 *

Also Published As

Publication number Publication date
WO2005033694A8 (en) 2006-05-04
WO2005033694A2 (en) 2005-04-14
EP1671116A2 (en) 2006-06-21

Similar Documents

Publication Publication Date Title
EP1750771A4 (en) Pancreatic islet microrna and methods for inhibiting same
EP2666859A3 (en) Pharmaceutical composition comprising anti-miRNA antisense oligonucleotides
WO2002002809A3 (en) Diagnosis of behavioural disorders, neurological disorders and cancer
WO2001077375A8 (en) Diagnosis of diseases associated with gene regulation
EP2631292A3 (en) Human microRNAs and methods for inhibiting same
WO2007091269A3 (en) NOVEL TANDEM siRNAS
EP2206781A3 (en) Antisense oligonucleotides for inducing exon skipping and methods of use thereof
WO2007112754A3 (en) Pharmaceutical compositions comprising anti-mirna antisense oligonucleotides
WO2005047477A3 (en) Interspersed repetitive element rnas as substrates, inhibitors and delivery vehicles for rnai
WO2003064626A3 (en) Double-stranded oligonucleotides
WO2001068912A3 (en) Diagnosis of diseases associated with tumor suppressor genes and oncogenes
EP1544297A3 (en) Medicament for treatment of Duchenne muscular dystrophy
WO2007031877A3 (en) Modulation of immunostimulatory properties of short interfering ribonucleic acid (sirna) by nucleotide modification
WO2006037462A3 (en) Cancer markers
WO2008008719A3 (en) Compositions and methods for inhibiting expression of the myc gene
WO2008086079A3 (en) Compositions comprising rnai and a neurotrophic factor and uses thereof
CN102482672A (en) Treatment of down syndrome gene related diseases by inhibition of natural antisense transcript to a down syndrome gene
EP2023937A4 (en) Rnai modulation of aha and therapeutic uses thereof
WO2001032832A3 (en) Antisense inhibition of nucleolin expression
WO2005073380A3 (en) Regulated polymerase iii expression systems and related methods
WO2008009477A3 (en) Means for inhibiting the expression of protein kinase 3
WO2008039937A3 (en) Blocking of gene expression in eukaryotic cells
WO2007044627A3 (en) Compositions and methods for delivery of interfering rna
WO2008001219A3 (en) Cancer therapy using bcl-xl-specific sina
WO2000015209A3 (en) REGULATION OF HER2/neu ONCONGENE EXPRESSION BY SYNTHETIC POLYAMIDES

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2004761503

Country of ref document: EP

CFP Corrected version of a pamphlet front page
CR1 Correction of entry in section i

Free format text: IN PCT GAZETTE 15/2005 UNDER (72, 75) REPLACE "WAN, JUN [CN/BE]" BY "WANG, JUN [CN/BE]"

WWP Wipo information: published in national office

Ref document number: 2004761503

Country of ref document: EP